May 13, 2022 Business News Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions LAVAL, QC and VAUGHAN, ON, May 10, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”) and Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) today announced the closing of…
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis